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Summary 
 
The objective of this review is to examine research exploring the decisions that women 
and couples make about prenatal screening and testing and the factors that influence 
their decisions. This will inform and offer context for the Nuffield Council of Bioethics’ 
inquiry on non-invasive prenatal testing (NIPT) and how its possible introduction into 
the NHS screening programme could affect decision-making in pregnancy. 
 
Studies deemed eligible for inclusion were full-length peer-reviewed journal articles 
and other publications in the English language that present data on parental decision-
making in the context of NIPT (for Down’s syndrome [DS], Edward’s syndrome [ES], 
and Patau syndrome [PS]), NIPD for other genetic conditions, and current prenatal 
screening and testing for DS. The shortage of studies about NIPT and NIPD means 
that sources are discussed from the UK and beyond. Publications that do not rely on 
primary empirical data were excluded. Given time and money constraints, publications 
were also excluded if focusing exclusively on scientific and clinical development and 
application, cost-effectiveness, marketing and commercial analysis, and bioethical 
considerations (although the latter topic is discussed in section five). 
 
Thirteen studies were found that explore the decision-making experiences of women 
in the context of NIPT for DS, ES, and PS. Positive experiences were often reported 
with respect to NIPT’s perceived accuracy, safety, and capacity to provide an earlier 
test result. However, women also identified several concerns requiring consideration 
before NIPT is introduced into the NHS screening programme. Both advantages and 
disadvantages of NIPT were also outlined in twenty-three studies examining peoples’ 
views of, and attitudes towards, NIPT for DS, ES, and PS. Many more studies examine 
expectant parents’ decision-making relating to current prenatal screening for DS and 
diagnostic testing, and whether to continue or terminate a pregnancy following a 
diagnosis of DS, ES, or PS. This literature from diverse disciplines sketches out key 
issues around choice, care, responsibility, parenting, and disability. After statistics of 
screening uptake and terminations of pregnancy in the UK are outlined, the evidence 
review identifies gaps in the literature that future research on NIPT could explore. The 
review concludes by suggesting that more research on the experiences and decision-
making processes of expectant parents with respect to NIPT – and on the opinions, 
anxieties, and suggestions of healthcare professionals and policymakers, charities, 
academics, and the wider public – a matter of urgency. Such studies will likely ignite 
more reflective and collective dialogues, and better communication between expectant 
parents and professionals, around NIPT and its implementation in NHS prenatal care. 
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1. NIPT for DS, ES, and PS 
 
1.1. Background 
NIPT is used to analyse cell-free foetal DNA in a pregnant woman’s blood at around 
ten weeks’ gestation. It can accurately predict the chance of a foetus having a genetic 
condition such as Down’s syndrome [DS], Edward’s syndrome [ES], or Patau 
syndrome [PS]. For example, at least 99 percent of all pregnancies in which a foetus 
has DS can be detected using NIPT. Screening for sex chromosome disorders (e.g. 
Turner syndrome) is also possible by using NIPT. Although most pregnant women will 
receive a ‘lower-risk’ (lower-chance) result, some will receive a ‘higher-risk’ (higher-
chance) result, meaning it is highly likely that a foetus has a genetic condition. In such 
instances, diagnostic testing (CVS or amniocentesis) is used to validate this (i.e. NIPT 
is not officially classified as a diagnostic test). As NIPT is non-invasive, it presents no 
risk of miscarriage or other adverse outcomes associated with diagnostic tests. If 
implemented in the NHS, NIPT is likely to be offered as a contingent screening test as 
this is viewed as being ‘cost-effective’ (Chitty et al. 2016).1 
 
It is worth clarifying the difference between NIPT and NIPD here. Both are based on 
a maternal blood test. However, in some cases (e.g. testing for achondroplasia), this 
test is diagnostic and will mean an invasive diagnostic test (amniocentesis or CVS) is 
not required to confirm a diagnosis. This is referred to as NIPD (outlined more fully in 
section 2). In other cases, such as testing for DS, this test is not diagnostic (i.e. it is a 
‘screening test’). This is referred to as NIPT. Since NIPT cannot provide a definite 
diagnosis, an invasive diagnostic test can be offered to confirm or refute a result. 
 
1.2. NIPT uptake statistics 
Statistics for NIPT uptake were difficult to locate, mostly since uptake is only available 
in commercial settings (so national screening statistics are not recorded) and a select 
few NHS hospitals. Some studies have provided uptake statistics for single settings, 
with Chetty et al. (2013) and Beamon et al. (2014) reporting a high uptake of NIPT in 
one hospital and Taylor et al. (2014) reporting a low uptake of NIPT in another hospital; 
the reasons behind these uptake rates are not empirically explored by any of these 
outputs. Chitty et al. (2016), however, provide more extensive uptake statistics as part 
of the RAPID (Reliable, Accurate Prenatal, Non-Invasive Diagnosis) programme. The 
RAPID research programme was a prospective cohort study performed in eight NHS 
hospitals from November 2013 to February 2015. The objective of the programme was 
to examine the potential costs and consequences of introducing NIPT in the NHS. 
Although NIPT may help detect other conditions – like ES and PS – the main aim of 
RAPID was to evaluate NIPT for DS. 
                                                            
1 For further resources, consult the website for the NHS RAPID Project (RAPID 2016). This contains an 
extensive electronic library with links to publications on cell-free foetal DNA, NIPT for Down’s syndrome 
[DS] and foetal sex determination, stakeholder views and ethical concerns relating to NIPT, NIPD for 
single gene disorders and foetal blood types, studies on subchromosomal changes and foetal 
genoming, and research on the cost-effectiveness and implementation of NIPT. 
5 
 
 
During the RAPID study, 40,527 pregnant women booked for maternity care at units 
participating in the study and 30,790 (76.0%) opted for DS screening. NIPT was 
offered to 3,175 women who received a screening result of at least 1:1000 (i.e. a 1 in 
1,000 chance of having a baby with DS). In this population, 934 had a result of higher 
than 1:150 (i.e. a 1 in 150 chance of having a baby with DS) and 695 (74.4%) of these 
consented to NIPT, with 166 (17.8%) choosing to have diagnostic testing only 
(amniocentesis or CVS) and 73 (7.8%) declining further testing altogether. Of the 
2,241 women with a risk between 1:150 and 1:1000, 1,799 (80.3%) had NIPT and of 
the women with a positive result, 80.4% underwent confirmatory diagnostic testing. In 
the participating units, uptake of diagnostic testing before the availability of NIPT was 
54% in women who received a (higher) risk result of at least 1:150. In the RAPID study, 
the uptake of follow-on testing overall (NIPT and diagnostic testing combined) in 
women with the same result was 92.5%. The RAPID programme suggests that NIPT 
uptake in the eight participating units was considerably higher than the national uptake 
rate for the current DS screening pathway (66.2%). 
 
The RAPID study found that 71 women received a confirmed diagnosis of DS; 13 out 
of 42 women (31%) with a diagnosis after NIPT and 2 out of 29 women (7%) after 
diagnostic testing continued their pregnancy, resulting in 12 live births of children with 
DS. For Chitty et al. (2016), this indicates that expectant women had NIPT to ‘prepare’ 
and not necessarily for decision-making about termination. They also suggest that this 
highlights how the birth rate of infants with DS may not change significantly if NIPT is 
introduced more widely, an observation in keeping with two regional US studies 
suggesting that NIPT has not affected the number of infants born with DS (Warsof et 
al. 2015; Wax et al. 2015) and one UK study showing that some women continued the 
pregnancy with a diagnosis of DS after NIPT (Gil et al. 2016). However, given the small 
numbers of cases, any conclusions should be drawn tentatively and the concerns of 
disability rights groups such as Saving Down Syndrome and Don’t Screen Us Out – 
that NIPT may lead to a reduction in the amount of children born with DS – are yet to 
be debated in extensive detail in the literature. 
 
1.3. Decision-making and NIPT 
Thirteen publications were identified that explored the decision-making processes of 
NIPT for DS, ES, and PS. Four of these publications draw on data from the UK (Gil et 
al. 2015; Lewis et al. 2016a, 2016b; Strange 2015), five from Hong Kong (Chan et al. 
2015; Lau et al. 2012, 2016; Poon et al. 2014; Yi et al. 2013), three from the US (Chetty 
et al. 2013; O’Brien et al. 2014; Vahanian et al. 2014), and one from Taiwan (Li et al. 
2015). Whilst five of the thirteen studies focus on the possible ‘predictors’ of decision-
making using quantitative data (Chan et al. 2015; Chetty et al. 2013; Gil et al. 2015; 
Poon et al. 2014; Vahanian et al. 2014), eight studies draw on qualitative data from 
pregnant women themselves that explains why they do or do not consent to NIPT (Lau 
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et al. 2012, 2016; Lewis et al. 2016a, 2016b; Li et al. 2015; O’Brien et al. 2014; Strange 
2015; Yi et al 2013). 
 
Research on the possible predictors of NIPT uptake suggest that expectant parents 
are more likely to accept NIPT if it is a first pregnancy (Chan et al. 2015; Poon et al. 
2014), if they receive an increased risk result for DS, ES, and/or PS (Gil et al. 2015), 
if they conceived via assisted reproductive procedures (Chan et al. 2015), if they are 
Caucasian or Asian (Chetty et al. 2013; Vahanian et al. 2014), if they have health 
insurance [mostly in the US] (Chetty et al. 2013; Vahanian et al. 2014), if they are older 
than 35 (Chetty et al. 2013; Gil et al. 2015), if they were university-educated (Gil et al. 
2015), and if they are employed (Poon et al. 2014). Other predictors that were reported 
as influencing choices include timing of results (first or second trimester) and nuchal 
translucency size. Most of the studies predicted a large decrease in diagnostic testing 
after the introduction of NIPT, but acceptance rates varied among studies; Vahanian 
et al. (2014), for example, report that 60% of their sample declined NIPT (mostly since 
women did not have insurance to cover the cost).  
 
Importantly, the research cited above does not ask why women have NIPT for DS, ES, 
and PS. This is explored by eight other studies (Lau et al. 2012, 2016; Lewis et al. 
2016a, 2016b; Li et al. 2015; O’Brien et al. 2014; Strange 2015; Yi et al 2013). Several 
of these studies reported women’s positive experiences of NIPT (often cited by authors 
by using the term ‘overwhelmingly positive’). In Lau et al.’s (2012) study, for instance, 
over 95% of participants ‘had complete or almost complete resolution of anxiety’ and 
said they would recommend NIPT to others. This corresponds with suggestions from 
some women that NIPT should be offered to all pregnant women on a routine basis 
(Lewis et al. 2016b). Women who had NIPT regularly reported that the most important 
aspects of NIPT were accuracy, safety, and having an earlier result (and that ultimately 
reduces the possibility of a diagnostic test). 
 
The reasons for women undertaking NIPT include seeking general reassurance and 
attempting to reduce uncertainty (Lewis 2016b; Yi et al. 2013; Strange 2015), a desire 
to obtain as much information about a foetus as possible (Lewis et al. 2016b), wanting 
to avoid anxiety about diagnostic testing that may cause a miscarriage (Lau et al. 2012, 
2016; Li et al. 2015; O’Brien et al. 2014; Yi et al. 2013), perceiving themselves as 
being at ‘advanced maternal age’ (O’Brien et al. 2014; Yi et al. 2013), wanting access 
to a safer and more accurate test than current screening (Lau et al. 2016; Lewis et al. 
2016b; Strange 2015; Yi et al. 2013), being designated as ‘higher-risk’ (Lewis 2016b), 
and informing decisions about further testing and continuing/terminating a pregnancy 
(Lewis et al. 2016b; Yi et al. 2013. Reasons for declining NIPT include testing causing 
anxiety (Lewis et al. 2016b), stating a preference for diagnostic testing that was seen 
as more accurate (O’Brien et al. 2014), the cost/lack of health insurance (O’Brien et 
al. 2014), a perception that an NIPT result would not change how they managed the 
pregnancy [e.g. they would not terminate following a diagnosis] (Lewis et al. 2016b; 
O’Brien et al. 2014), and satisfaction with earlier screening results (Lewis et al. 
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2016b)2. In some studies, a small number of participants were more uncertain about 
whether to have NIPT, indicating anxiety and ‘decisional conflict’ (Lewis et al. 2016b). 
 
On the issue of informed consent, Lewis et al. (2016a) reported that ‘rates of informed 
consent were high (89%)’, although they suggest that more research on this in other 
clinical settings is needed. They claimed that whilst many women demonstrated a 
good knowledge about NIPT, others deemed to not to have made an ‘informed choice’ 
often did not deliberate about the test and had poor knowledge of it. In a Hong Kong 
study, Lau et al. (2016) describe how women valued both ‘individual autonomy’ and 
‘relational autonomy’ (i.e. with help from others such as doctors [as ‘experts’], partners, 
and other women on internet discussion groups) in decision-making for NIPT. Women 
in their study wanted more support from others to make sense of complex information 
and guide their decision, thereby highlighting how the concept of ‘non-directive care’ 
does not always translate to other contexts (e.g. rather than just providing expectant 
parents with clinical leaflets on NIPT). 
 
Despite women’s positive experiences, several studies identify a number of concerns 
about NIPT including the presence of anxiety – even following a ‘lower-risk’ result (Lau 
et al. 2012; Strange 2015; Yi et al. 2013), worries about how commercial companies 
advertise NIPT (Yi et al. 2013), difficulty in interpreting risk-ratios that consist of a wide 
range of probabilities (Yi et al. 2013), a lack of knowledge about the conditions tested 
for (Strange 2015), the potential for health inequalities with the introduction of NIPT 
(Yi et al. 2013), a lack of follow-up care after a result (Yi et al. 2013), and the perception 
that the turnaround time for results was too short (Lau et al. 2012; Lewis et al. 2016b). 
In Lau et al.’s (2016) study, women reported that they were unaware that NIPT 
provides results for ES and PS and that doctors were unable to offer information about 
these conditions in a way that they could understand (likewise, Yi et al. claim that in 
their study, mothers were worried that their professionals were not well informed about 
NIPT). Others expressed ethical concerns, such as a possible increase in termination 
rates (Lewis et al. 2016b), an unease around whether NIPT will result in ‘eliminating’ 
DS (Lewis et al. 2016b), and whether women would feel pressure to accept NIPT since 
it is defined as lower-risk (Lewis et al. 2016b). 
 
Furthermore, Strange’s (2015) study identifies how both healthcare professionals and 
expectant parents believe NIPT (and also NIPD) prompts deep critical examination of 
its moral, social, and political implications – not only of the technology but of the 
established clinical practices and specific policy contexts within which it has emerged. 
In one of the few studies to quote more ‘dissenting’ voices from women that are more 
critical of/ambiguous about NIPT, Strange shows how NIPT troubles the boundaries 
between screening and diagnostic testing, ignites worries about NIPT’s routinisation 
                                                            
2 Other studies have predicted why NIPT is declined. For example, Taylor et al. (2014) deduce that in 
their US study, 72% of 961 expectant parents declined NIPT and elected for ‘standard’ screening 
processes because of no insurance coverage, a desire to undertake screening that includes ultrasound, 
not wanting to terminate a pregnancy, and a lack of recommendation from their healthcare professional. 
8 
 
and trivialisation, and provokes important ethical questions that demand attention. In 
addition, according to Strange, giving full responsibility for decision-making to women 
means that NIPT can cause them to feel silenced and stigmatised when deciding after 
diagnostic testing and a subsequent diagnosis to terminate a pregnancy. 
 
1.4. Attitudes and views of NIPT 
Twenty-three studies were identified which examined peoples’ attitudes towards NIPT 
for DS, ES, and PS. Of this research, only one was undertaken with pregnant women 
who had already consented to NIPT in a current pregnancy (Lau et al. 2012). Fourteen 
of the twenty-two studies were carried out with pregnant women (Farrell et al. 2014; 
Floyd et al. 2016; Hill et al. 2012b, 2016; Kooij et al. 2009; Lewis et al. 2013, 2014b; 
Sahlin et al. 2016; Silcock et al. 2014; Tischler et al. 2011; van Schendel et al. 2015; 
Verweij et al. 2013a,  2013b; Yotsumoto et al. 2012), one with pregnant women and 
their male partners (van Schendel et al. 2014), one with mothers of children with DS 
(Kellogg et al. 2014), and five with members of the public (Allyse et al. 2015; Farrimond 
and Kelly 2011; Higuchi et al 2016; Kelly and Farrimond 2012; Sayres et al. 2014). 
One study was also identified which examined pregnant women’s views of NIPT for 
sex chromosome conditions and microdeletion syndromes (Agatisa et al. 2015). There 
is also a small body of literature on the views of healthcare professionals in relation to 
NIPT including genetic counsellors, consultants, nurses, midwives, and obstetricians 
(Alexander et al. 2014; Buchanan et al. 2014; Hill et al. 2012a, 2013, 2016; Horsting 
et al. 2014; Musci et al. 2013; Sayres et al. 2011; van den Heuvel 2010). However, 
this work will not summarised here as this review directs attention to the experiences 
and views of expectant parents. 
 
Fifteen studies were carried out with pregnant women (one with pregnant women and 
male partners) to examine their views on NIPT. Many studies report that these women 
viewed NIPT as a positive development in prenatal care and that they would consider 
taking it themselves, even if they did not have screening in earlier pregnancies (Farrell 
et al. 2014; Kooij et al. 2009; Lewis et al. 2013, 2014b; Sahlin et al. 2016; Tischler et 
al. 2011; van Schendel et al. 2014, 2015; Verweij et al. 2013a, 2013b; Yotsumoto et 
al. 2012). They cited its positive qualities in relation to safety (Lewis et al. 2013, 2014b; 
Tischler et al. 2011; van Schendel et al. 2014), accuracy (Floyd et al. 2016; Lewis et 
al. 2013; Verweij et al. 2013b), timing (Farrell et al. 2014; Hill et al. 2012b; Lewis et al. 
2013; van Schendel et al. 2014; Yotsumoto et al. 2012), its capacity to provide 
information (Lewis et al. 2014b; Sahlin et al. 2016) and potentially detect conditions 
beyond DS, ES, and PS (Farrell et al. 2014; Hill et al. 2012b, 2016; Sahlin et al. 2016; 
van Schendel et al. 2014), and allowing parents to prepare for diagnostic testing and 
possibly continuing or terminating a pregnancy (Floyd et al. 2016; van Schendel et al. 
2015). Such statements were commonly made with reference to the disadvantages of 
invasive diagnostic testing. Expectant parents’ hypothetical decision to have NIPT was 
influenced by the factors outlined above as well as maternal age (Tischler et al. 2011), 
education (Tischler et al. 2011), ethnicity (Tischler et al. 2011), perceptions of health 
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and the quality of life of a foetus/baby (Lewis et al. 2014b; Sahlin et al. 2016), whether 
they felt that they could bring up child with a disability (Lewis et al. 2014b), personal 
values and experiences of disability and/or termination (Lewis et al. 2014b; Sahlin et 
al. 2016; Tischler et al. 2011), conversations with a partner (Lewis et al. 2014b), and 
previous pregnancy experiences (Lewis et al. 2014b).  
 
However, there were concerns about NIPT regarding diagnostic testing after a higher-
risk result (Farrell et al. 2014), lack of knowledge about NIPT among pregnant women 
(Yotsumoto et al. 2012), compromising informed consent since women may just agree 
with a professionals’ endorsement (Tischler et al. 2011), the routinisation and 
trivialisation of testing (Lewis et al. 2013; van Schendel et al. 2014, 2015; Yotsumoto 
et al. 2012), the possibility of inaccurate results (Floyd et al. 2016), unequal access 
because of cost (Yotsumoto et al. 2012), creating a pressure to have NIPT since it is 
seen as ‘just a blood test’ (Lewis et al. 2013; van Schendel et al. 2014), increasing 
anxiety even among low-risk populations (Floyd et al. 2016; Lewis et al. 2013), and 
the difficulty of determining quality of life and severity of a genetic condition in advance 
(van Schendel et al. 2014). Other concerns include ethical worries pertaining to 
‘eugenics’ (Floyd et al. 2016), screening for late onset disorders and non-medical sex 
selection (Kooij et al. 2009), the continued stigmatisation/discrimination of disabled 
people and worries over DS being ‘eliminated’ (Lewis et al. 2013; van Schendel et al. 
2014, 2015), where the medical profession ‘draws the line’ relating to prenatal testing 
(Lewis et al. 2013; van Schendel et al. 2014), and women not being able to fully realise 
the consequences and choices they will perhaps unexpectedly be confronted with 
(Kooij et al. 2009; van Schendel et al. 2014; Yotsumoto et al. 2012). 
 
Whilst some expectant parents were generally uninterested or ambivalent about NIPT 
(Tischler et al. 2011), others wanted more clarification, such as what conditions could 
be screened for and the quality of life of the child born with a condition (Farrell et al. 
2014). Others shown discrepancies between healthcare professionals and expectant 
parents. For example, in contrast to their providers, women in studies by Hill et al. 
(2012b, 2016), Silcock et al. (2014), and Yotsumoto et al. (2012) were willing to wait 
longer for test results with lower accuracy if the test had no miscarriage risk, whereas 
for health professionals, accuracy and early testing were of more importance. 
 
Only one study was identified which examines the views of parents with DS regarding 
NIPT (Kellogg et al. 2014). They found that whilst many parents would perhaps use 
NIPT in future pregnancies, they were worried that NIPT could lead to increased 
terminations, increased stigma, and decreased availability of services for individuals 
with DS. Many also reported healthcare professionals giving biased, incorrect, and 
overly negative about DS in their pregnancy, suggesting that NIPT will only be useful 
if accompanied by accurate, complete, and impartial information about the condition. 
As for more ‘general public’ views, some studies reported that they believed women 
would decide on accepting/declining NIPT with reference to personal and religious 
beliefs (particularly relating to perceptions of disability and DS specifically), trust in the 
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medical system, attitudes towards risk, and knowledge about NIPT and the conditions 
possibly detected through its use (Allyse et al. 2015; Higachi et al. 2016). 
 
Some members of the public supported NIPT use, particularly in terms of offering 
‘choice’ through the use of a safer and more accurate test, and expressed an interest 
in it themselves (Higachi et al. 2016; Kelly and Farrimond; Sayres et al. 2014). But 
others voiced concerns over financial cost (Allyse et al. 2015), the value of prenatal 
genetic information (Allyse et al. 2015), the trivialisation of testing (Farrimond and Kelly 
2011), possibly increased anxiety for women and partners (Kelly and Farrimond 2012), 
and the implications of commercial availability of NIPT (Farrimond and Kelly 2011; 
Kelly and Farrimond 2012). Others were worried about NIPT playing a role in creating 
a negative image of people with a diagnosis (Higachi et al. 2016) and its connection 
to eugenic reasoning (Kelly and Farrimond 2012), the speed at which NIPT is being 
developed which could outstrip the capacity of professionals to ensure that women are 
informed (Higachi et al. 2016), information and support requirements for expanded 
testing (Kelly and Farrimond 2012), and NIPT fostering a view that all women should 
undertake the procedure (Higachi et al. 2016). Research shows, then, how members 
of the public both support and question NIPT. Farrimond and Kelly (2011) found, for 
example, that NIPT is concurrently seen as a tool in the ongoing societal discrimination 
against the disabled (linked to the notion of ‘eugenics’), a positive technique that can 
offer reassurance, a medical option only justified for ‘severe’ genetic conditions, and 
a valid expansion of personal choice. 
 
Finally, one study was identified which examines pregnant/recently delivered women’s 
views of NIPT for sex chromosome conditions and micro-deletion syndromes – i.e. not 
DS, ES, or PS (Agatisa et al. 2015). Although the women largely supported NIPT for 
sex chromosome conditions, they were more uncertain about NIPT for micro-deletion 
syndromes as it only reveals variable or unknown phenotypic expression of a condition 
in a child. That said, they would be keen to receive details of all conditions assessed 
by NIPT prior to testing. They also said in their own experience (10 of the 31 women 
had NIPT in an earlier pregnancy), they were familiar with DS, ES, and PS but not sex 
chromosome conditions or micro-deletion syndromes. Without knowledge of this, the 
women worried that others would not be able to make an ‘informed’ choice and Agatisa 
et al. suggest that this is problematic because NIPT is likely to increase the volume of 
information that must be conveyed during the counselling process. 
 
1.5. NIPT in the commercial sector 
Access to NIPT in the UK is primarily through the commercial sector. The numbers of 
expectant parents accessing NIPT in the commercial sector is unavailable. However, 
suggestions are that there has been an ‘extraordinary uptake’ of NIPT in the at-risk 
population worldwide (Gil et al. 2013; Larion et al. 2014; Sago et al. 2014; Warsof et 
al. 2015), with estimations that more than half a million NIPT procedures have been 
performed in over 61 countries (Chandrasekharan et al. 2014; Zhang et al. 2015). In 
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the UK, equally, whilst the average cost of NIPT in the commercial sector has not been 
calculated, it has been suggested that it can vary between £400 and £900 (ARC 2016; 
Morris et al. 2014). In their analysis of internet advertising by commercial companies 
and health providers for NIPT, Skirton et al. (2014) found that whilst several sites 
provide balanced and accurate information, most do not provide supporting evidence 
to underpin details, overstate the capabilities of NIPT (e.g. that it can ensure ‘normality 
of foetal chromosomes’), and do not always abide by professional recommendations. 
Many sites also include persuasive advertising, such as discussing NIPT’s benefits 
more than its limitations or the possible implications for expectant parents – this 
reflecting claims of a study on how the UK press media report advances in NIPT (Lewis 
et al. 2014a). It was noted that very little empirical research has been carried out on 
the implications for the NHS of women seeking NIPT in the commercial sector, such 
as how they attempt to access follow-up advice and/or care. 
 
1.6. Conclusion 
Studies on the experiences of expectant parents relating to NIPT are limited in scope 
and is often closely associated with scientific research programmes (e.g. RAPID). No 
data was identified on what expectant parents do following a higher-risk NIPT result 
for DS, ES, and PS (or any other genetic conditions) with respect to diagnostic testing 
and continuing or terminating a pregnancy. Chitty et al. (2016) outline some statistics 
relating to this, and Lewis et al. (2016a) suggest that uptake rates following a higher-
risk result were high in their study, yet no studies were found that examine expectant 
parents’ decision-making processes in this context.  
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2. NIPD 
 
2.1. Background 
NIPD is a test that involves analysing cell-free foetal DNA (cffDNA) in maternal blood 
during pregnancy. It is offered in the UK (NHS) to determine foetal sex in pregnancies 
at risk of serious X-linked conditions (including Duchenne muscular dystrophy) and 
congenital adrenal hyperplasia (CAH). It is also used for RhD-women with a history of 
haemolytic disease in a newborn or with high levels of anti-D antibodies in pregnancy. 
The development of NIPD for single gene disorders is also progressing and available 
for a small number of genetic conditions, such as achondroplasia. 
 
2.2. NIPD uptake statistics 
No statistics were identified that recorded uptake rates of NIPD for different conditions 
in either the NHS or commercial sector. A possible reason for this is the wide range of 
conditions screened for with NIPD. However, research by Hill et al. (2014a, 2014b, 
2015) suggests that introducing NIPD into routine practice may be accompanied by 
an increase in the uptake of prenatal testing for single gene disorders. Their survey 
study indicates that of 131 carrier or affected adults with cystic fibrosis [CF], only 
43.5% participants would have diagnostic testing for CF. In contrast, 94.9% of the 
sample said they would hypothetically choose NIPD for CF – and that 90% would be 
prepared to pay for it. For Hill et al., this suggests that a high potential uptake of NIPD 
includes couples who would currently decline diagnostic testing (due to a miscarriage 
risk) but would have NIPD. Their work claims that introducing NIPD for CF would be 
welcomed and uptake is likely to be high, but they recognise that the predicted uptake 
may differ from actual uptake (linking to previous research showing that hypothetical 
interest is often only a modest predictor of actual uptake). 
 
2.3. Parents’ Views and Experiences of NIPD 
Little research has established parental views and experiences of NIPD. Three studies 
were identified that explore NIPD experiences of pregnant women and/or partners 
(Lewis et al. 2012a, 2012b, 2014c) and five others examine the views of NIPD of those 
with direct experience of conditions (Hill et al. 2014a, 2014b, 2015; Oxenford et al. 
2013; Skirton et al. 2014). No studies were identified that examine the decision-making 
processes of expectant parents after a positive NIPD result (i.e. whether they continue 
or terminate a pregnancy). 
 
In a study by Lewis et al. (2012a, 2012b) on NIPD for foetal sex determination, they 
found that decision-making was influenced by several factors including the number of 
previous pregnancies, earlier pregnancy experiences (e.g. miscarriage, termination), 
and personal experience and perceived seriousness of the condition. The technology 
was viewed by women as ‘overwhelmingly positive’ because it expanded reproductive 
choice, was perceived as safe, and allowed them to receive an earlier result. The latter 
was seen as offering an opportunity to be reassured, delay attachment to a pregnancy, 
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and prepare for next stage of pregnancy and beyond. Other perceived benefits were 
it allowed men to be informed about being a carrier of a genetic condition and it could 
help with treatment of ‘at-risk’ women during a pregnancy (including CAH carriers). 
However, participants also recognised some potential disadvantages of using NIPD 
for foetal sex determination, such as feeling pressure from family members to have 
testing, concerns over foetal sexing and technology misuse, and increased anxiety. 
 
In another study, Lewis et al. (2014c) reported on the experiences of eight women 
using NIPD who were at risk of single gene disorders such as achondroplasia, Apert 
syndrome, thanatophoric dysplasia, and a neuromuscular condition. They liked access 
to an accurate, safe, and early test and highlighted the benefits of NIPD over 
diagnostic testing, including minimising the risk of miscarriage and having earlier 
procedures which reduces uncertainty and worry in the first trimester. However, they 
also identified several concerns such as what conditions are tested for prenatally and 
how this is decided (recognising the importance of guidelines for this), who should be 
offered NIPD, and fears about the relative ease and risk-free nature of the test which 
may lead to the trivialising of NIPD. In all of these studies, they suggest that further 
research on stakeholders’ views and experiences of NIPD is warranted to inform the 
possible widespread implementation of NIPD for a range of genetic conditions. 
 
Five studies were found that explore the views of NIPD of those with direct experience 
of conditions. In their survey-based study on NIPD for CF, Hill et al. (2014b, 2015) 
found that common reasons for wanting NIPD for CF include preparing for the birth of 
a baby and to ‘help make a decision about whether or not to continue the pregnancy’. 
Participants also described other ‘benefits’ of NIPD for CF including the reduced risk 
of miscarriage (since they would not be offered diagnostic testing), the perception that 
NIPD would be a safe and simple test, and that NIPD would be earlier in a pregnancy 
than diagnostic testing. Most concerns with NIPD, albeit small in number according to 
Hill et al. (2014b, 2015), include a worry about terminations for CF and the possibility 
of increasing pressure to terminate (more were worried about the routinisation of NIPD 
and pressure to have the procedure). Hill et al, (2014b) also identify a discrepancy in 
the preferences of potential users and healthcare professionals, with users preferring 
a test with no risk of miscarriage and professionals preferred a test that was accurate 
and early. Additionally, whilst most users thought NIPD for CF should be offered to all 
women, more health professionals thought NIPD should be reserved for known carrier 
couples. 
 
Two papers examined the views of NIPD of 27 carriers of thalassaemia, sickle cell 
disease, CF, or spinal muscular atrophy (Hill et al. 2014a; Skirton et al. 2014). Using 
focus groups and interviews, they found participants gave ‘overwhelming support’ to 
NIPD for single gene disorders. Nonetheless, parents were wary of tests becoming 
routine, felt that the decision about NIPD should be made by both parents but that 
women ultimately have the right to make the decision, and believed that the interests 
of the mother and foetus outweigh fathers and that fathers who declined carrier testing 
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should be made aware that an NIPD result may reveal their carrier status (they were 
more divided on who should provide this information – i.e. the partner or professional). 
The participants’ concerns also revolved around the accuracy of NIPD and that less 
thought may be afforded to having a blood test compared to a diagnostic test – and 
that the perceived ease of a blood test may subsequently bring increased pressure to 
have NIPD. However, they also felt that NIPD would eliminate the risk of miscarriage 
(and ease anxieties about current diagnostic testing) and could be carried out earlier 
in a pregnancy which allowed parents to ‘prepare’ for decision-making and/or their 
future child.  
 
Finally, one paper was identified that examines women’s preferences and needs for 
the routine implementation of foetal Rhesus-D (RhD) typing using NIPD (Oxenford et 
al. 2013). They perceived this as a positive development and that it should be offered 
to all RhD– women. Test accuracy was important to participants yet their knowledge 
was described as ‘poor’. For example, although 90.7% of participants knew that the 
baby could have a different blood group from themselves, only 34% knew that blood 
groups are inherited from both parents. In addition, many women were uncertain about 
whether they would have NIPD for RhD themselves because they would not want an 
extra blood test and that they wanted more information on its benefits, risks, accuracy, 
and implications. Finally, Oxenford et al. warned that women may accept whatever is 
recommended to them and that NIPD could be presented as routine care, thereby 
undermining the principle of informed consent – concluding that this needs addressing 
before any test is fully introduced into clinical practice. 
 
2.4. Conclusion 
Although a number of studies highlight the benefits of NIPD for expectant parents, they 
also recognise the concerns of using it in routine prenatal care. Very little research is 
accessible at the moment and more is needed before the technique is possibly made 
more widely available. 
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3. Decision-Making and Current Screening/Testing for DS 
 
3.1. Background 
In this section, the evidence review revisits significant issues from previous debates 
about prenatal screening and testing for Down’s syndrome [DS]. All expectant parents 
in the UK are offered screening for DS. The main objective of screening is to identify 
women in whom a risk factor is deemed high enough to warrant offering diagnostic 
testing. Screening should take place in a window of ten to twenty weeks during a 
pregnancy, although the preferred period of time is by the end of the first trimester. If 
expectant parents undertake screening, they receive a ‘risk factor’, a numeric ratio 
establishing the odds of a foetus having DS. This works by combining a prior 
probability – maternal age at expected date of delivery – with a likelihood ratio based 
on several factors such as weight, gestation, ethnicity, pregnancy history, smoking 
habits, the number of foetuses, whether it is an assisted conception, and nuchal 
translucency size. These create an estimate of whether a foetus has DS (and also 
possibly Edward’s syndrome [ES] and Patau syndrome [PS]). In the UK, the cut-off 
point for categorising a pregnancy as ‘at-risk’ is 1:150 (a 1 in 150 risk of having a foetus 
with DS, ES, and/or PS). If expectant parents receive a risk factor that is numerically 
higher than 1:150 (e.g. 1:250), they are categorised as ‘lower-risk’ and they are not 
offered further treatment except for an ultrasound at twenty weeks to check for other 
potential problems (anomaly scan). In contrast, if expectant parents receive a risk 
factor that is numerically lower than 1:150 (e.g. 1:100), they are categorised as ‘higher-
risk’ and diagnostic testing (i.e. amniocentesis or CVS) is offered to prove or refute a 
suspected diagnosis. 
 
An amniocentesis involves taking a small sample of amniotic fluid by passing a fine 
needle through the abdomen of an expectant mother and drawing the fluid out using 
a syringe. During CVS, a small sample of placenta is taken either by passing a small 
needle through the abdomen of an expectant mother and drawing the fluid out using 
a syringe, or by passing a small tube through a vagina and cervix. CVS is carried out 
in the first trimester and an amniocentesis is often carried out in the second trimester. 
Both tests provide an accurate diagnosis but have a few possible complications such 
as causing miscarriage, infection, bleeding, and premature labour. The risk of causing 
miscarriage is reported as 1% due to amniocentesis and 2% due to CVS. Diagnostic 
testing is offered because of a possible indication of a genetic condition, previous or 
current pregnancy complications, a family history of a condition, and an advanced 
maternal age (although this last option is currently not common in UK medicine). After 
diagnostic testing is done, samples are sent to a cytogenetics laboratory for analysis. 
After a result is established, information is returned to professionals who must deliver 
this news to expectant parents. If a diagnosis is established, counselling is offered 
before a decision has to be made about whether to continue or terminate a pregnancy. 
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3.2. Decision-making and screening/testing for DS 
There is a small collection of literature reviews and meta-syntheses that reflect on the 
factors that influence decisions related to current NHS screening and/or testing for DS 
(more on PS and ES later). The most comprehensive reviews of the literature on DS 
screening and testing (but mostly screening) include Reid et al. (2009), Skirton and 
Barr (2007), Crombag et al. (2013), and Thomas (2014b). The reviews show that much 
of the research on this topic derives from many different countries (and with diverse 
social, cultural, economic, political, medical contexts), uses qualitative and quantitative 
methods (but rarely together), focuses on screening and testing at different periods of 
gestation, and stems from scholarly roots such as sociology, public health, medicine 
(midwifery, nursing, genetics), anthropology, psychology, and bioethics. The quality of 
this evidence seems high, especially given the sheer amount of data from the UK and 
beyond – and that many studies from around the world report similar/related findings. 
 
3.2.1. Accepting screening/testing for DS 
According to the literature, common justifications for consenting to screening and/or 
testing include offering reassurance that a foetus is unlikely to have DS (Bryant et al. 
2010; Etchegary et al. 2008; García et al. 2008; McNeill et al. 2009; Pilnick et al. 2004; 
Santalahti et al. 1998), satisfying curiosity about a foetus (Skirton and Barr 2007; van 
den Berg et al. 2005a), fulfilling demands of a partner (Helm et al. 1998; Jaques et al. 
2004), a perceived negative attitude towards DS and disability more generally (García 
et al. 2008; Gottfreðsdóttir et al. 2009b), allowing expectant parents to ‘prepare’ for a 
possible diagnosis and to subsequently terminate early in a pregnancy (Etchegary et 
al. 2008; Williams et al. 2005), and a fear of supporting and parenting a child with a 
disability (Bryant et al. 2010; Chiang et al. 2006; García et al. 2008; Pilnick and Zayts 
2012; Remennick 2006). This ‘tentativeness’ (Rothman 1986) is often felt by expectant 
mothers. Within a gendered context, responsible mothering implies the acquisition of 
all available medical information about the health of a foetus (García et al. 2012) and 
engaging with prenatal medicine to potentially produce a ‘normal’ baby (Gottfreðsdóttir 
et al. 2009b). This means that women are likely to shoulder a moral duty to prevent 
what is perceived to be the burden of a disabled child on their family – and, so, feel to 
blame if this is not achieved (Alderson 2001; Chiang et al. 2006; García et al. 2012; 
Ivry 2006; Landsman 2009; Reed 2012; Remennick 2006). A similar fear is reported 
by expectant parents with previous pregnancy complications or a family history of 
genetic conditions, citing this when accounting for a decision to have screening and/or 
testing (McNeill et al. 2009; Spencer 2002). One of the most common justifications for 
participating in screening and testing is that expectant mothers perceive themselves 
as being at an ‘advanced maternal age’ as this is the only known attribute increasing 
the risk of a foetus being diagnosed with DS (Kaiser et al. 2004; Lotto 2015; McNeill 
et al. 2009; Thomas in press). 
 
In the context of diagnostic testing (CVS/amniocentesis), reasons for consenting to a 
test include – as well as many of the reasons outlined above – resolving uncertainty 
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and doubt, believing that it was recommended by a professional (either explicitly or 
implicitly), the belief that a prenatal diagnosis will help professionals to prepare for 
delivery and that it will help themselves to plan their future of parenting a child with a 
disability, perceiving that the ‘risk’ of miscarriage is low and/or that it offsets the ‘risk’ 
of having a child with DS, the strong influence of partners, the inclination to terminate 
a pregnancy if a diagnosis is established, and not wanting to ‘disappoint’ professionals 
(Browner and Preloran 1999; Markens et al. 2010; Press and Browner 1998; Rapp 
2000; Rothman 1986). It should be noted here that decision-making processes are 
immensely complex, and expectant parents are likely to account for their decision with 
reference to many of these explanations. Indeed, they are frequently conflicted about 
‘whether to know or not to know’ (Aune and Möller 2012; Kaiser et al. 2003; Markens 
et al. 1999). 
 
Several studies appear to view consenting to DS screening and/or testing as a result 
of rational decision-making processes. However, others identify how screening (and 
testing in some cases too) is an instance of conformity instead of being an expression 
of choice (Chiang et al. 2006; Gottfreðsdóttir et al. 2009b; Markens et al. 1999; 
Marteau 1995; Pilnick 2004; Pilnick et al. 2004; Press and Browner 1997; Rapp 2000; 
Santalahti et al. 1998; Sooben 2010; Williams et al. 2005). Many studies suggest that 
expectant parents accept DS screening as it is perceived as a ‘routine’ procedure in 
prenatal care (Barr and Skirton 2013; Chiang et al. 2006; Markens et al. 1999; Pilnick 
et al. 2004; Thomas in press; Williams et al. 2005). Hunt et al. (2005) claim that 
expectant parents do not have a clear understanding of screening as they view it as a 
recommended part of prenatal care. This relates to them interpreting screening and/or 
testing as an advised part of pregnancy surveillance (Hunt et al. 2005; Vassy 2006), 
how expectant parents do not discuss screening and/or testing prior to the procedure 
(Gottfreðsdóttir et al. 2009b), how they can be overloaded with information which 
reduces the time to discuss and think more about screening (Barr and Skirton 2013), 
how they view professionals’ offer of screening/testing as endorsing its acceptance 
(Heyman et al. 2006; McNeill et al. 2009; Remennick 2006), and how ultrasound scans 
used for screening can be seen, first and foremost, as offering a chance for ‘meeting 
the baby’ and to make a pregnancy seem more real rather than for prenatally detecting 
genetic conditions (Barr and Skirton 2013; Draper 2002; Heyman et al. 2006; Lupton 
2013; Mitchell and Georges 1998; Reed 2012; Thomas in press; Williams et al. 2005). 
 
In a similar vein, Tsouroufli (2011) claims that expectant parents accept screening 
because of their prompt processing in the hospital, because professionals endorse it 
as a safe test (no chance of miscarriage), and because professionals expect that that 
they will opt for the procedure. These studies collectively convey a concern that 
expectant parents do not perceive their care as non-directive; they argue that stating 
options does not always amount to the neutral provision of advice since some options 
have the force of an explicit instruction (Browner et al. 1996; Helm et al. 1998; Hunt et 
al. 2005; Lippman 1991; Marteau et al. 1993; Tsouroufli 2011; Williams et al. 2002c), 
so they may not feel empowered by screening or testing (Lippman 1994; Pilnick 2008; 
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Rapp 2000; Rothman 1986; Williams et al. 2002c). Baillie et al. (2000) and Åhman et 
al. (2010) believe that the routinisation of DS screening as a ‘normal’ part of pregnancy 
means that expectant parents are not always aware of, or prepared for, the complex 
information and choices associated with a result.  
 
Many studies report how screening, for example, prompts feelings of anxiety among 
expectant parents before, during, and after receiving a lower-risk result or higher-risk 
result for DS (Aune and Möller 2012; Green and Statham 1996; Ivry 2006; Markens et 
al. 1999; Marteau 1995; Pilnick et al. 2004). For Heyman et al. (2006) and Hunt et al. 
(2005), this angst and upset frequently emerges following a higher-risk result and a 
decision needing to be made about diagnostic tests. In the case of a diagnosis being 
made after testing, parents may feel that they are becoming ‘moral pioneers’ who must 
make a decision about the value of their own child (Rapp 2000; Rothman 1986). This 
literature demonstrates that whilst expectant parents may engage with screening 
and/or testing to decrease anxiety and receive reassurance, it can also have the 
opposite effect: they can be anxious about waiting for results, confronted with 
distressing decisions that they may not expect, and apprehensive and fearful even 
after a lower-risk result (Burton-Jeangros et al. 2013; Marteau 1995; Pilnick et al. 2004; 
Remennick 2006; Williams et al. 2005). 
 
3.2.3. Informed choice and non-directive care 
Whilst some research shows that non-directive or informed choice are not ‘achieved’ 
when screening and/or testing for DS, others explain that this should not always be 
defined as bad practice (Williams et al. 2002b). During interviews with professionals, 
Schwennesen and Koch (2012: 283) recognise that by answering expectant parents’ 
appeal for direction, professionals can move closer to promising ‘informed choice’ by 
supporting them to make decisions on the basis of uncertain knowledge. This shows 
how non-directive care may not always be the most suitable response to fully support 
expectant parents in decision-making. Nonetheless, many studies highlight how DS 
screening and/or testing presents problems such as how professionals have their own 
ambiguities and ethical concerns about screening and/or training (Thomas in press), 
are undertrained in communicating information (Cleary-Goldman et al. 2006; Sandall 
et al. 2001; Skirton and Barr 2007), and hold limited knowledge of DS (Dormandy et 
al. 2006; Skirton and Barr 2010) and screening for the condition (Ekelin and Crang-
Svalenius 2004; Farsides et al. 2004; Hey and Hurst 2003; Samwill 2002; Smith et al. 
1994; Williams et al. 2002c). This involves having little direct contact during medical 
training with people who have developmental disabilities (Cleary-Goldman et al. 2006; 
Driscoll et al. 2009; Skotko 2005). 
 
3.2.2. Declining screening/testing for DS 
Studies also report why expectant parents do not have DS screening. Common 
justifications include avoiding adverse health risks associated with diagnostic testing 
such as causing a miscarriage (Liamputtong et al. 2003; Markens et al. 1999; Pilnick 
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et al. 2004), the inaccuracies and unreliability of tests (Gottfreðsdóttir et al. 2009a), a 
lack of information on tests (García et al. 2008), concerns about the emotional impact 
of intervention (Markens et al. 1999; McNeill et al. 2009; Santalahti et al. 1998; van 
den Berg et al. 2005a), the complexity and inconclusiveness of information provided 
(Baillie et al. 2000; Heyman et al. 2006; Liamputtong et al. 2003; Markens et al. 1999; 
Remennick 2006), expectant parents ruling out the option of terminating a pregnancy 
(Etchegary et al. 2008; Heyman et al. 2006; Markens et al. 1999; McNeill et al. 2009; 
van den Berg et al. 2005a), friends’ negative experiences of screening (Santalahti et 
al. 1998), personal and/or religious values about the worth of children with DS and 
other disabilities (Bryant et al. 2010; Gottfreðsdóttir et al. 2009a; Liamputtong et al. 
2003; Remennick 2006), and a perception that DS is a condition not severe enough 
to terminate a pregnancy (Etchegary et al. 2008; García et al. 2008; Gottfreðsdóttir et 
al. 2009a; Santalahti et al. 1998). 
 
Decisions for refusing diagnostic tests include concerns about miscarriage and other 
‘risks’ (Browner and Preloran 1999; Browner and Press 1996; Lewando-Hundt et al. 
2001; Markens et al. 1999), expectant parents’ interpretation that they are ‘low-risk’ 
and a prenatal diagnosis is improbable (Markens et al. 2010), religious background 
(Press and Browner 1998), an objection to a termination of pregnancy on any grounds 
(Press and Browner 1998), and personal attributes of expectant parents such as social 
class, ethnicity, and social status (Rapp 2000; Remennick 2006). In their study on 
women’s decision to accept or decline amniocentesis, Markens et al. (2010) claim that 
the hypothetical willingness to terminate a pregnancy was only a partial explanation of 
the decision to decline amniocentesis. Rather, they found that the decision to decline 
was often based on their scepticism towards doctors (e.g. they can make mistakes) 
and medical technologies and trust in their own embodied and experiential knowledge 
that the pregnancy is progressing well. In contrast, women who accepted diagnostic 
tests accounted for their decision by conveying a strong trust in doctors/medicine (and 
did not trust embodied or experiential sources) and by appealing for the information 
and reassurance that they expected the procedure to provide. 
 
These studies identify how decision-making processes in the context of screening and 
testing for DS are complex and changing, with expectant parents likely to justify their 
choice with reference to any number of these rationalisations. Regarding the quality 
of information/counselling when expectant parents consider DS screening, studies 
claim that professionals have difficulty in communicating screening information whilst 
remaining non-directive and ensuring informed choice (García et al. 2008; Heyman et 
al. 2006; Pilnick et al. 2004; Thomas in press). This stems from the conflict between 
the time that professionals have available to explain screening and the time needed 
to discuss the procedure (Barr and Skirton 2013; Sooben 2010; Vassy 2006; Williams 
et al. 2002a), the trouble of conveying complex information (Burton-Jeangros et al. 
2013; Ekelin and Crang-Svalenius 2004; Heyman et al. 2006; Hunt et al. 2005), 
communication breakdowns when expectant parents’ first language is not the native 
language (Barr and Skirton 2013; Hey and Hurst 2003), and the different definitions 
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between expectant parents and professionals of what constitutes a ‘normal result’ 
and/or ‘normal child’ (Hunt et al. 2005; Vassy 2006; Williams 2006). Additionally, 
studies show how some professionals do not know how to best support higher-risk 
expectant parents (Getz and Kirkengen 2003; Williams et al. 2002a, 2002c), how some 
expectant parents are not fully aware of the key features of DS prior to screening and 
testing (Williams et al. 2002c), and how expectant parents may not fully understand 
screening (Burton-Jeangros et al. 2013; Gammons et al. 2010; van den Berg et al. 
2005b). 
 
3.3. Decision-making and continuing/terminating a pregnancy for DS 
In their integrative review of decision-making after a prenatal diagnosis of DS, Choi et 
al. (2012) identify 11 studies (9 quantitative, 2 quantitative and qualitative) in 7 different 
countries that met their inclusion criteria. Whilst some of these studies were based on 
hypothetical situations (Bell and Stoneman 2000; Bryant et al. 2005; Lawson 2006; 
Lawson and Walls-Ingram 2010; Leung et al. 2004; Roberts et al. 2002), others 
concerned people who made a decision after a prenatal diagnosis (Britt et al. 2000; 
Korenromp et al. 2007; Quadrelli et al. 2007; Zlotogora 2002). Other studies not 
included in Choi et al.’s review examine how and why expectant parents choose to 
terminate a pregnancy after a diagnosis of DS (Helm et al. 1998; Skotko 2005; Tymstra 
et al. 2004) and the views of parents of children with DS around terminating for the 
condition (Ahmed et al. 2013)3. 
 
Across the studies, a common reason for terminating a pregnancy after a diagnosis of 
DS was already having existing children and the perceived burden of a disabled child 
to parents, partners, and family members (Bryant et al. 2005; Britt et al. 2000; 
Korenromp et al. 2007; Lawson 2006; Lawson and Walls-Ingram 2010; Roberts et al. 
2002). Other reasons for terminating a pregnancy include the perception that the child 
with DS would have a reduced ‘quality of life’, the prognosis of DS is too severe and 
uncertain, worry about what would happen to the child after the parent/s died, and 
negative personal and public attitudes of disability (Korenromp et al. 2007; Lawson 
2006).  
 
Reasons for continuing a pregnancy after a diagnosis of DS include religious beliefs 
(Bryant et al. 2005; Helm et al. 1998; Lawson 2006; Leung et al. 2004), not wanting to 
experience a termination or being unable to decide on it, seeing the foetus/baby on a 
monitor and feeling foetal movement/heartbeat (Helm et al. 1998), changing their view 
after meeting a child with DS (Tymstra et al. 2004), previous infertility (Helm et al. 
1998), positive attitudes towards DS (Helm et al. 1998; Lawson 2006; Lawson and 
Walls-Ingram 2010), a perception that DS still entails a good ‘quality of life’ (Bell et al. 
                                                            
3 Lotto (2015) has carried out research on parents’ decision-making after a suspicion or diagnosis of a 
‘severe congential anomaly’. This includes DS, ES, and PS (as well as conditions such as anencephaly, 
spina bifida, and exomphalus). However, Lotto’s study – whilst highlighting reasons for terminating a 
pregnancy – is not prominent in this review as the specific condition was not always clear in participants’ 
accounts (and the focus in this review is specifically on DS, ES, and PS). 
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2000), and previous positive experiences of DS (Ahmed et al. 2013; Bryant et al. 2005; 
Helm et al. 1998; Lawson and Walls-Ingram 2010; Skotko 2005). Support from 
partners, family, friends, professionals, and others was also seen by most studies to 
influence the decision to continue or terminate a pregnancy. However, many parents 
also expressed doubt about the decision. Common reasons for this include conflicting 
feelings, disagreements with a partner, possible stigmatisation because of termination, 
and worries that they would be ‘killing a baby’ (Korenromp et al. 2007; Lotto 2015). 
 
The studies on parental decision-making following suspicion or diagnosis of a genetic 
condition are small in number but it is worth noting that the reasons for terminating a 
pregnancy are multiple and are unlikely to be fully covered by the research cited in this 
evidence review. 
 
3.4. Decision-making and Edward’s syndrome/Patau syndrome 
Many studies explore factors influencing decisions related to current NHS screening 
by only referencing DS. Whilst a small number of studies make reference to Patau 
syndrome [PS] and/or Edward’s syndrome [ES], very few explore parents’ experiences 
of being screened specifically for both genetic conditions. This reflects how DS is the 
primary ‘target’ of prenatal screening practices and how literature frequently still refers 
to screening/testing solely in terms of DS (Lotto 2015). Indeed, in one study (Walker 
et al. 2008), parents believed that they were being screened solely for DS and did not 
realise that they were also being screened for ES (but had a prenatal diagnosis of ES). 
 
In the small amount of research carried out with parents whose child was prenatally 
diagnosed with ES or PS4, they suggest that whilst some healthcare professionals 
were empathetic, considerate, and supportive of decision-making (Adler and Kushnick 
1982; Walker et al. 2008), others tried to coerce them into termination and claimed 
their child would probably die after birth (Guon et al. 2013; Janiver et al. 2012; Walker 
et al. 2008), despite recent evidence suggesting the condition is not always ‘lethal’5 
and up to 20% of children survive for more than a year (Wilkinson et al. 2014). The 
studies show how parents felt their child was not valued by healthcare professionals, 
felt poorly informed about screening and falsely reassured by professionals after initial 
results, were unhappy with how a diagnosis and prognosis were communicated (very 
negative), were not made aware of all options and were offered fewer treatments (e.g. 
C-section not being offered when the foetus/baby was in distress), and believed that 
some professionals were biased towards certain options (Guon et al. 2013; Janiver et 
al. 2012; Walker et al. 2008). Despite such experiences, a large number of parents 
continued with the pregnancy (for possible reasons for this, see: Guon et al. 2013). 
 
                                                            
4 Côté-Arsenault and Denney-Koelsch (2016) discuss both conditions but they categorise them with 
other ‘lethal foetal diagnoses’. As such, it is impossible to distinguish ES and PS from their arguments. 
5 Wilkinson et al. (2014) suggest avoiding the term ‘lethal’ when referring to conditions like ES or PS 
since there is no agreement about a definition of lethal malformations, nor which conditions should be 
included in this category. They suggest that counselling should be mainly focused on prognosis instead. 
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A small number of publications cite single cases relating to ES or PS (Heyman et al. 
2006; Pilnick and Zayts 2016). Other single cases include parents’ reflections about 
their experience of prenatal care when their child was diagnosed, or suspected as 
having, PS or ES. Whilst some parents felt well-supported (Locock et al. 2005), others 
felt judged by their decision to continue a pregnancy, believed that treatment to save 
their child’s life was withdrawn, had insensitive and rude comments from professionals 
who did not look beyond their child’s genetic label, and could only access accurate 
information online (Farlow 2009, 2011; Thiele 2010)6. In several of the studies cited 
above, parents that continued a pregnancy conveyed that they had ‘few regrets’ and 
that they lived happy, fulfilling lives with their child. This reflects positive accounts of 
parents who have a child with DS, documented in studies (Ahmed et al. 2013; Flaherty 
and Glidden 2000; Skotko 2005; Solomon 2012; Thomas 2014a; Van Riper and Choi 
2011) and autobiographies (for references to these books, see: Thomas in press). 
 
However, in many of the same accounts, parents of children with DS suggested that 
their experiences of healthcare professionals during screening and testing was mixed. 
Some professionals were empathetic and supportive; they conveyed a diagnosis in 
person, provided informed information on the condition, and referred parents to a local 
support group (Skotko 2005). Other parents, however, explain that some professionals 
did not support their decision to continue a pregnancy and felt judged for doing so, 
they delivered a diagnosis via telephone rather than in person (seen as inconsiderate), 
they expected parents to terminate a pregnancy and focused mostly on termination in 
conversations with them, they held negative attitudes about DS and used problematic 
language (e.g. apologising when delivering a diagnosis, using negative terms such as 
‘mongoloid’), they focused solely on ‘negative’ biomedical information and screening 
for DS as opposed to the condition itself, and they provided inaccurate, insensitive, 
inconsistent, and outdated information about DS (e.g. Skotko 2005; Tymstra et al. 
2004; Williams et al. 2002b). This correlates with studies arguing that leaflets for DS 
screening contain false, misleading, and inconsistent information on DS (Bryant et al. 
2001; Murray et al. 2001; Williams et al. 2002b). 
 
4. Statistical Data on Current Screening/Testing for DS, ES, and PS 
 
The most recent official statistics report that roughly 74% (N=542,312) of all expectant 
mothers accessing NHS services in England and Wales in 2011 opted to be screened 
for DS (NHS FASP 2012)7. The uptake in screening increased annually in England 
                                                            
6 Other experiences of parents whose child was diagnosed with ES/PS are reported in HealthTalk.org, 
an online resource that provides ‘free, reliable information about health issues by sharing people’s real 
life experiences’. For people who continued or terminated a pregnancy after a diagnosis of ES, see: 
Healthtalk.org (2016a, 2016b, 2016e, 2016f, 2016g, 2016h). For people who continued or terminated a 
pregnancy after a diagnosis of PS, see: Healthtalk.org (2016c, 2016d). 
7 DS screening uptake statistics in Scotland or Northern Ireland could not be identified. However, the 
National Services Division (2011) claims that 34,768 expectant mothers in Scotland were screened for 
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and Wales between 2007 (53%) and 2011. Whilst 2008 and 2009 saw uptake rates of 
57% and 62% respectively, an uptake rate of 70% was recorded in 2010 (NHS FASP 
2012)8. The UK NSC (2013) claims that around 567,000 women in England and Wales 
were screened for DS in 2013 (uptake rate is not officially recorded, but the reported 
birth rate of 698,500 in 2013 suggests this is around 81%). More recent publications 
claim that the current national update rate for both the first trimester combined screen 
and second trimester quadruple test is 66% (Chitty et al. 2016), although the source 
of this is unclear. Research suggests around two to three percent of pregnant women 
in England and Wales that consent to screening receive a higher-risk result (Chitty et 
al. 2016; NHS FASP 2012) and approximately 54% of expectant parents will undertake 
invasive prenatal testing after a positive screen result (Chitty et al. 2016). According 
to Buckley and Buckley (2008), between 1 in 20 and 1 in 30 higher-risk results lead to 
a diagnosis of DS9. Annual statistics on the average gestational age of women having 
diagnostic testing, the exact number of diagnostic tests performed, and the number of 
women receiving a confirmed diagnosis after diagnostic testing could not be identified. 
 
A report conducted by the National Down’s Syndrome Cytogenetic Register (Morris 
and Springett 2014) claims that in 2013 in England and Wales, there were 1,886 
diagnoses of DS, 65% of which were prenatal (N=1,232), a rate of 2.7 per 1,000 births. 
The number of diagnoses has increased gradually over the years, as has the number 
of those detected prenatally. There were 1,066 diagnoses in 1989 (30% detected 
prenatally), 1,228 diagnoses in 1994 (49% detected prenatally), 1,313 diagnoses in 
1999 (55% detected prenatally), 1,417 diagnoses in 2003 (59% detected prenatally), 
1,791 diagnoses in 2007 (62% detected prenatally), and 1,959 diagnoses in 2011 
(65% detected prenatally). There was also an estimated 728 live births (live birth rate 
of 1.0 per 1,000 live births). This has varied over the years but has remained 
consistent. Estimated live births of babies with DS were 750 in 1989, 639 in 1994, 604 
in 1999, 616 in 2003, 723 in 2007, and 758 in 2011. 
 
Both prenatal and postnatal diagnoses of PS in England and Wales have remained 
fairly stable since 2004 (when statistics were first collected). There were 145 
diagnoses in 2004 (92% detected prenatally), 189 in 2006 (90% detected prenatally), 
189 in 2008 (90% detected prenatally), 221 in 2010 (90% detected prenatally), and 
180 in 2013 (91% detected prenatally). Estimated live birth rates have been stable. 
There were an estimated 14 live births in 2004, 25 in 2006, 24 in 2008, 28 in 2010, 
and 19 in 2013. Between 2004 and 2013 in England and Wales, there have been 
1,892 diagnoses of PS and an estimated 233 live births. Both prenatal and postnatal 
diagnoses of ES in England and Wales have also remained stable since 2004 (when 
statistics were first collected). There were 356 diagnoses in 2004 (90% detected 
                                                            
DS in 2010-2011. It is worth noting, however, that such statistics do not represent all procedures in 
Scotland since it is limited to those collected by nationally designated laboratories. 
8 These statistics do not include those who accessed prenatal screening in privately-funded clinics. 
9 Suspicions of DS can also be established during an anomaly scan that is performed at twenty weeks 
gestation. 
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prenatally), 454 in 2006 (87% detected prenatally), 489 in 2008 (92% detected 
prenatally), 542 in 2010 (90% detected prenatally), and 474 in 2013 (93% detected 
prenatally). Estimated live birth rates have also been stable. There were an estimated 
40 live births in 2004, 69 in 2006, 48 in 2008, 66 in 2010, and 40 in 2013. Between 
2004 and 2013 in England and Wales, there have been 4,818 diagnoses of ES and 
an estimated 524 live births. 
 
Of the 1,232 prenatal diagnoses of DS, 90% were terminated (N=925), 8% were live 
births (N=82), and 2% were natural miscarriages or stillbirths (N=20); the outcome of 
205 prenatal diagnoses is unknown (Morris and Springett 2014). The proportion of 
terminations after a diagnosis of DS in England and Wales has remained steady for 
over twenty years (and the miscarriage/stillbirth and live birth rates have subsequently 
remained steady too). From the first report in 1989 until 2013, the annual rates for 
termination in England and Wales have ranged from 89% to 95% (the mean rate is 
92%). Termination statistics for PS and ES could not be identified. 
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5. Gaps in the Evidence 
 
Given that the introduction of NIPT (and NIPD) into clinical practice is in its infancy, 
the current lack of studies around expectant parents’ experiences of the procedure is 
understandable. More research is needed to ensure that the opinions, concerns, and 
suggestions of expectant parents, healthcare professionals, and others (policymakers, 
disability rights groups, etc.) are identified. The current research shortage ensures that 
there are many gaps in the analysis of NIPT that merit attention. 
 
For instance, exploring the use of NIPT with respect to the characteristics of mothers 
(class, ethnicity, age, education, etc.) and studying the perspectives of others such as 
partners, who are often overlooked in studies on NIPT (Skirton and Patch 2013), could 
provide interesting insights. It could also be useful to explore what implications the 
availability of NIPT in commercial settings has for those involved, such as how NIPT 
is delivered, how it is marketed and regulated, and what effects private provision has 
for training healthcare professionals to offer this service. It could be useful to explore 
whether people can access NIPT owing to financial restrictions (Chandrasekharan et 
al. 2014; Rolfes and Schmitz 2016). 
 
In addition, current gaps in the research include explorations of whether much-debated 
issues in prenatal care, such as the capacity to offer expectant parents truly ‘informed 
consent’ and ‘non-directive care’ and how screening can create anxiety for parents, 
emerge in undertaking NIPT. Since NIPT is reported as having a 99 percent detection 
rate for DS, for example, it could be productive to get a grasp of how this knowledge 
is managed by pregnant women. There are concerns that rolling out NIPT for ‘low-risk 
women’ (as research has mostly been carried out among ‘high-risk’ populations so 
far), which involves screening at an earlier gestation and reducing possible ‘risks’ such 
as miscarriage via diagnostic testing, may create added pressure to have NIPT. Thus, 
studies may profit by examining how much expectant parents reflect on undertaking 
NIPT before consenting to the procedure and what happens when there is a higher-
risk result. Current research also overlooks how expectant parents do (or would) 
understand and deal with inconclusive results, ‘variants of uncertain significance’ (i.e. 
variation in the normal gene sequence, the significance of which is unknown), and 
‘incidental findings’ (undiagnosed medical conditions that are found unintentionally). 
Such research could be carried out using observational qualitative data since this is 
not used in any current publications on NIPT – and could highlight issues that emerge 
when professionals and expectant parents interact with one another in the clinical 
setting (e.g. what ‘informed choice’ in the context of NIPT looks like in practice). 
 
Another gap in the research is the various ethical issues of NIPT in practice. There is 
a relatively large literature on the ethical issues of NIPT from scientists, bioethicists, 
healthcare professionals, and academics (Benn and Chapman 2009; Chapman and 
Benn 2013; Bryant 2014; de Jong and de Wert 2015; de Jong et al. 2010, 2011, 2015; 
Deans and Newson 2012; Deans et al. 2012, 2015; Dickens 2014; Dondorp et al. 
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2015; Gekas et al. 2016; Hall et al. 2010; Munthe 2015; Newson 2008; Rolfes and 
Schmitz 2016; Schmitz et al. 2009; Tasinato et al. 2011; Thomas and Rothman 2016; 
Twiss et al. 2014; Verhoef et al. 2016). However, all of these are not grounded in 
empirical data and, for the most part, do not figure in many public debates about NIPT, 
with ‘ethics’ predominantly being discussed in relation to the bioethical principles of 
reproductive autonomy and informed consent. 
 
What could also be profitable for future research on NIPT is how expectant parents 
and healthcare professionals manage the capacity of NIPT to detect genetic conditions 
other than DS, ES, and PS, and how they feel about the possibility of expanding NIPT 
to include next-generation sequencing10 or microarray testing11 which make it feasible 
to screen for deletions and duplications in the foetal genome. This could explore their 
views of who decides what conditions to screen for, what information will be shared 
(and if expectant parents have the ‘right to (not) know’), whether the technology may 
be used for other purposes (e.g. sex selection), and what support is needed in order 
to fully understand different results. This also relates to a current dearth of studies on 
incidental maternal cancer diagnoses following discordant NIPT results (Bianchi et al. 
2015). More research could examine the possible psychosocial effects of this and the 
impact of ‘over-diagnosis’ for women who must respond to this information. 
 
Of interest could be how much training professionals receive before delivering NIPT 
and how they respond to concerns raised by disability rights groups that NIPT extends 
an ‘informal’ eugenics. On this point, a current gap in the research is a consideration 
of the possible values that are embedded in NIPT (with the exception of Strange 2015). 
Future studies could attend to expectant parents’ and healthcare professionals’ 
attitudes toward disability in the context of NIPT to ensure that information about 
conditions is accurate, informative, and as impartial as possible to help expectant 
parents come to a decision from a more nuanced and knowledgeable position. This is 
important amidst concerns that prenatal settings offer little opportunity for people to 
discuss and explore their beliefs about disability (Bryant et al. 2006; Farrelly et al. 
2012). 
 
Finally, a current research gap is the relationship of NIPT with pregnancy termination 
and how this is regularly divorced from public debates about reproductive techniques, 
despite being intimately tied up with them. Research captures, both in the context of 
NIPT and earlier prenatal techniques, that termination is located in a context of secrecy 
and shame (Lotto 2015; Strange 2015). Whilst termination is a difficult and problematic 
topic, studies on NIPT have not explored it in detail. Doing so could also help 
                                                            
10 Next-generation sequencing (NGS) is a catch-all term used to describe a range of different techniques 
that allow for DNA sequencing (defined as the process of separating the different pieces of DNA). The 
sequence reveals the kind of information that is carried in a particular DNA segment. 
11 Chromosomal microarray analysis is a technique used to identify extra or missing chromosomal 
segments. It can be used with living individuals who do not have a specific diagnosis but who have 
attributes such as unexplained developmental delay and intellectual disability. 
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policymakers think about whether current regulatory frameworks (e.g. Abortion Act 
1967) should be revisited owing to NIPT being introduced into clinical practice. 
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6. Conclusion 
 
This review has identified the current research on expectant parents’ decision-making 
in relation to NIPT (for DS, ES, and PS), NIPD (for rare genetic conditions), and earlier 
forms of prenatal screening/testing (for DS, ES, and PS) – together with the current 
research gaps. With NIPT minimising physical risks (such as reducing the number of 
diagnostic tests and miscarriages as a result of having this test) and offering an earlier 
result, one could reasonably deduce that the number of expectant parents that choose 
to undertake screening will expand. If we also consider the pace of developments in 
prenatal care in recent years, the widespread implementation of NIPT for DS and other 
conditions may occur sooner than expected. Therefore, more studies on the opinions, 
anxieties, and suggestions of expectant parents and healthcare professionals along 
with policymakers, charities, academics, and the wider public – with respect to NIPT 
– is a matter of urgency. This is particularly important in the knowledge that there were 
687,852 births in England and Wales in 2015 (ONS 2016), highlighting the large 
number of pregnant women that would be offered NIPT in the future. Many of the gaps 
identified in section five currently sit at the margins of public debate and offer starting 
points for future research. This will ignite more reflexive and collaborative dialogues – 
and better communication between professionals and parents – around NIPT and its 
implementation in NHS prenatal care. 
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3.5. Summary 
The many considerations identified above highlight how healthcare professionals play 
a key role in screening and testing for genetic conditions – and how a suspected or 
concrete diagnosis is communicated. This offers vital key points for consideration with 
respect to the future of NIPT. This is particularly important in light of research findings 
suggesting that some expectant parents do not differentiate between the results from 
screening and diagnostic testing – such as interpreting a higher-risk screening result 
as a definitive diagnosis (Levenson 2014; Lewando-Hundt et al. 2001; Pilnick et al. 
2004) – with this distinction becoming even more blurred in the context of NIPT and 
subsequent highly accurate results (e.g. reported as 99% for DS). 
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